Clinical Trials
32 trialsCabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors
National Health Research Institutes, Taiwan
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
SWOG Cancer Research Network
ACTION-1
RayzeBio, Inc.
LAMPARA
Columbia University
OXTEND-01
Debiopharm International SA
RIALTO
Grupo Espanol de Tumores Neuroendocrinos
CLARINET
Ipsen
A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
Dana-Farber Cancer Institute
SAUNA
University Hospital, Antwerp
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
SCRI Development Innovations, LLC
PLANET
Duke University
REMINET
Federation Francophone de Cancerologie Digestive
ELECT
Ipsen
NET729
Ipsen
SPINET
Ipsen
A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.
Saint John's Cancer Institute
LOLA
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
MetNET-2
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Circulating Tumor Cells and Tumor DNA in HCC and NET
University of Aarhus
Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis
Ipsen
Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours
Ipsen
ATLANT
Ipsen
TELEFIRST
European Organisation for Research and Treatment of Cancer - EORTC
SAPHE
Ipsen
POSEIDON
Ipsen
CALM-NET
Ipsen
Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET
Samsung Medical Center
MERGE
Samsung Medical Center
PHRC-Merkel
University Hospital, Grenoble
SUNLAND
GERCOR - Multidisciplinary Oncology Cooperative Group
SS-HCC
Federico II University
ATG1line
Federico II University